Study of the AQP4 expression in traumatic brain edema and multimodal MRI imaging

The aquaporin-4(AQP4)is a highly selective membrane protein.It is important for the body to maintain the water balance between internal and external environment of cells,the studies have found that the abnormal expression of AQP4 is related to the occurrence of many diseases.The cerebral edema is the most common and serious complication of brain trauma,and its pathogenesis is closely related to AQP4.The development of multimodal magnetic resonance imaging(M-MRI)could been provided imaging basis for accurate diagnosis of traumatic brain edema.In recent years,the correlation between AQP4 and M-MRI has become a hotspot of research.This paper reviews the research progress on the correlation between AQP4 expression in traumatic cerebral edema and M-MRI.

Azvudine reduces the in-hospital mortality of COVID-19 patients:A retrospective cohort study

In our retrospective cohort study,we aim to explore whether Azvudine modifies the risk of death in COVID-19 patients.It was conducted on the medical records of patients,consecutively admitted for COVID-19 pneumonia to two hospitals in Chongqing,China.Based on Azvudine treatment exposure,the patients were divided into Azvudine group and non-Azvudine group.We used 1:2 ratio propensity score matching(PSM)in our study to adjust for confounding factors and differences between Azvudine and non-Azvudine groups.There were 1072 patients included in our original cohort.With 1:2 ratio PSM,the Azvudine group included 195 patients and non-Azvudine group included 390 patients.The results showed that Azvudine treatment was associated with improved in-hospital mortality in overall population(OR 0.375,95%CI 0.225-0.623,P<0.001),severe subgroup(OR 0.239,95%CI 0.107-0.535,P=0.001),critical subgroup(OR 0.091,95%CI 0.011-0.769,P=0.028)in matched cohort with univariate analysis.And there was a significantly lower in-hospital mortality in overall population(11%vs.24%,P<0.001),severe sub-group(10%vs.32%,P<0.001)and critical sub-group(5%vs.34%,P=0.017)in matched cohort.These results suggest Azvudine can reduce in-hospital mortality in overall COVID-19 patients,severe,and critical subgroup population.